[Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebo-controlled, multicenter, randomized trial].

Broncho-munal OM-85 acute respiratory infections bacterial lysate efficacy safety treatment

Journal

Terapevticheskii arkhiv
ISSN: 0040-3660
Titre abrégé: Ter Arkh
Pays: Russia (Federation)
ID NLM: 2984818R

Informations de publication

Date de publication:
23 Nov 2023
Historique:
received: 22 11 2023
accepted: 22 11 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 30 12 2023
Statut: epublish

Résumé

To evaluate the efficacy and safety of OM-85 in the treatment of uncomplicated acute respiratory infections (ARI) in adults. A double-blind, placebo-controlled, multicenter, randomized trial included 556 patients (18-60 years old) with mild and moderate ARI and negative results of polymerase chain reaction analysis for SARS-CoV-2 RNA and rapid test for influenza A and B viruses. Patients were randomized into two groups: in the first group ( The superiority of OM-85 over placebo by primary endpoint was observed on the 5th, 7th and 10th days of treatment. OM-85 efficacy has also been proven by secondary criteria. OM-85 shortened the time until the symptoms of ARI resolved according to the WURSS-21 and CCQ, increased the proportion of patients with body temperature below 37°C by 2-9 days. The time needed to resolve the symptoms of disease in 20% of patients according to WURSS-21 was 7 and 9 days in patients taking OM-85 and placebo, respectively. Bacterial lysate increased the probability of complete disappearance of symptoms according to CCQ by 45.7% compared to placebo. The analysis of the frequency and severity of adverse events, laboratory tests, physical and instrumental examination results during treatment confirmed the good tolerability and safety of OM-85. The study confirmed the efficacy and safety of OM-85 in the complex treatment of ARI in adults. Цель. Оценить эффективность и безопасность бактериального лизата ОM-85 в терапии неосложненных острых респираторных инфекций (ОРИ) у взрослых. Материалы и методы. В двойное слепое плацебо-контролируемое многоцентровое рандомизированное исследование включили 556 пациентов (18–60 лет) с легкими и среднетяжелыми ОРИ и отрицательными результатами анализа методом полимеразной цепной реакции на наличие РНК SARS-CoV-2 и экспресс-теста на вирусы гриппа А и В. Больных рандомизировали в две группы: в 1-й (

Autres résumés

Type: Publisher (rus)
Цель. Оценить эффективность и безопасность бактериального лизата ОM-85 в терапии неосложненных острых респираторных инфекций (ОРИ) у взрослых. Материалы и методы. В двойное слепое плацебо-контролируемое многоцентровое рандомизированное исследование включили 556 пациентов (18–60 лет) с легкими и среднетяжелыми ОРИ и отрицательными результатами анализа методом полимеразной цепной реакции на наличие РНК SARS-CoV-2 и экспресс-теста на вирусы гриппа А и В. Больных рандомизировали в две группы: в 1-й (

Identifiants

pubmed: 38159017
doi: 10.26442/00403660.2023.10.202464
doi:

Types de publication

English Abstract Journal Article

Langues

rus

Sous-ensembles de citation

IM

Pagination

850-858

Auteurs

O V Kalyuzhin (OV)

Sechenov First Moscow State Medical University (Sechenov University).

A V Gorelov (AV)

Sechenov First Moscow State Medical University (Sechenov University).
Central Research Institute of Epidemiology.
Yevdokimov Moscow State University of Medicine and Dentistry.

A G Malyavin (AG)

Yevdokimov Moscow State University of Medicine and Dentistry.

A A Zaytsev (AA)

Burdenko Main Military Clinical Hospital.
Russian Biotechnological University (ROSBIOTECH).

E V Esaulenko (EV)

Saint Petersburg State Pediatric Medical University.

K E Novak (KE)

Saint Petersburg State Pediatric Medical University.

A S Bykov (AS)

Sechenov First Moscow State Medical University (Sechenov University).

Classifications MeSH